Olympus had agreed to sell its microscope unit to private equity firm Bain Capital for $3.1 billion as it speeds up the overhaul of its business portfolio to focus solely on medical technology
The microscope unit, which also manufactures industrial endoscopes and x-ray analyzers, will be transferred to Bain on January 4, subject to antitrust regulatory approvals in Japan and elsewhere.
Olympus stated that the transfer to Bain would benefit the company by allowing it to grow through more agile and flexible decision-making based on market needs.
Bain edged global private equity firms such as Carlyle Group and KKR & Co. for the right to acquire the microscope unit.
Olympus said the transfer to Bain would be in its best interest to allow the business to grow with more agile and flexible decision-making based on market needs.
Bain won over global private equity firms such as Carlyle Group and KKR & Co.
Bain owns flash memory chip maker Kioxia Holdings and is proceeding to a second bidding round for Toshiba.


Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 



